The Urgency of Compulsory Licensing Provision for Transfer of Technology in the Pandemic Treaty:...
Guest blog by Ronald Eberhard
The Intergovernmental Negotiating Body, established by the World Health Assembly, aims to draft a global pandemic prevention, preparedness, and response...
Ensuring that intellectual property rights aren’t a barrier to scaling-up: the remarkable example of...
This week various international bodies are tackling different challenges in meeting the urgent problem of scaling-up manufacture of and access to vaccines for Covid-19....
Will Europe block the Pandemic Agreement because of one word?
This commentary originally appeared in the Brussels Times, and is available here.
The Pandemic Agreement negotiations began in December of 2021. Sufficiently motivated by the...
The European Commission says Covid-19 vaccines should be global public goods, but do their...
The European Commission has entered into advance purchase agreements (APAs) for Covid-19 vaccines with six pharmaceutical companies and is concluding negotiations with two companies....
Gilead’s sofosbuvir patent in India – options for global access to new hepatitis C...
Earlier this month the US pharmaceutical company Gilead obtained a patent in India for sofosbuvir, part of a treatment of hepatitis C that became...
Medicines Law & Policy welcomes WHO’s Solidarity Call to Action to realise equitable global...
The World Health Organization today with Costa Rica launched the "COVID-19 Technology Access Pool (C-TAP)" to ensure that knowledge, data and intellectual property are...
Medicines price transparency: Ground still left to cover
Parts of this blog were previously published in the Lancet Regional Health Europe
Secret medicines prices are hotly debated as European health systems struggle to...
Some Surprises in the European Commission’s New Intellectual Property Strategy
The European Commission's new intellectual property (IP) strategy is out and it holds a number of surprises for access to medicines. After restating the...
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...
Transfer of technology and know-how for the production of pandemic-related health products in the...
A version of this brief was published on 13 June '25 by the Graduate Institute as part of their 'Governing Pandemic Snapshot' series: https://www.governingpandemics.org/gp-snapshot
During...